Herriot Tabuteau
Known title: Chief Executive OfficerCIK: 0001219927
Associated companies
Transaction History
| AXSM | ▲ Buy | Option Exercise | 4,660 | $23K | 8/6/2026 | View on chart |
| AXSM | ▼ Sell | Open Market | 4,660 | $997K | 8/6/2026 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 45,004 | $223K | 8/5/2026 | View on chart |
| AXSM | ▼ Sell | Open Market | 45,004 | $9.5M | 8/5/2026 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 49,666 | $246K | 7/1/2026 | View on chart |
| AXSM | ▼ Sell | Open Market | 49,666 | $11.9M | 7/1/2026 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 49,670 | $246K | 6/9/2026 | View on chart |
| AXSM | ▼ Sell | Open Market | 49,670 | $12.0M | 6/9/2026 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 32,410 | $260K | 2/2/2026 | View on chart |
| AXSM | ▼ Sell | Open Market | 32,410 | $6.0M | 2/2/2026 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 31,261 | $251K | 1/7/2026 | View on chart |
| AXSM | ▼ Sell | Open Market | 31,261 | $5.3M | 1/7/2026 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 29,450 | $236K | 1/6/2026 | View on chart |
| AXSM | ▼ Sell | Open Market | 29,450 | $5.1M | 1/6/2026 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 78,703 | $631K | 1/5/2026 | View on chart |
| AXSM | ▼ Sell | Open Market | 78,703 | $13.5M | 1/5/2026 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 10,558 | $85K | 12/4/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 10,558 | $1.6M | 12/4/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 20,163 | $3.0M | 12/3/2025 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 20,163 | $162K | 12/3/2025 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 49,252 | $395K | 12/2/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 49,252 | $7.1M | 12/2/2025 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 21,775 | $175K | 11/5/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 21,775 | $2.9M | 11/5/2025 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 50,459 | $405K | 11/4/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 50,459 | $6.8M | 11/4/2025 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 91,705 | $735K | 11/3/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 91,705 | $12.1M | 11/3/2025 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 12,774 | $102K | 10/8/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 12,774 | $1.5M | 10/8/2025 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 13,390 | $107K | 10/7/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 13,390 | $1.6M | 10/7/2025 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 19,220 | $154K | 10/6/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 19,220 | $2.3M | 10/6/2025 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 19,719 | $158K | 9/16/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 19,719 | $2.3M | 9/16/2025 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 15,254 | $122K | 9/15/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 15,254 | $1.8M | 9/15/2025 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 27,907 | $224K | 9/12/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 27,907 | $3.3M | 9/12/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Deutsche Bank cuts Axsome Therapeutics price target to $267
Deutsche Bank maintained its positive stance on Axsome Therapeutics but lowered its price target to $267. This adjustment comes as the stock trades near a key support level, with recent technical signals indicating a rejection at that price point. While other analysts continue to highlight the company's potential, the latest target remains below the current average analyst estimate.
Deutsche Bank cuts Axsome Therapeutics price target to $267. Deutsche Bank maintained its positive stance on Axsome Therapeutics but lowered its price target to $267. This adjustment comes as the stock trades near a key support level, with recent technical signals indicating a rejection at that price point. While other analysts continue to highlight the company's potential, the latest target remains below the current average analyst estimate.